Eiger BioPharmaceuticals, Inc. (EIGR)
| Market Cap | 344.19M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -63.17M |
| Shares Out | 29.88M |
| EPS (ttm) | -2.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $10.39 |
| Previous Close | $10.44 |
| Change ($) | -0.05 |
| Change (%) | -0.48% |
| Day's Open | 10.50 |
| Day's Range | 9.97 - 10.69 |
| Day's Volume | 87,251 |
| 52-Week Range | 4.55 - 13.99 |
Two new breakout stocks for Week 1 of 2021 with better than 10% short-term upside potential. The MDA breakout picks completed 2020 up +73.4% beating the S&P 500 for the 4th consecutive year wi...
Eiger is solely focused on rare disease opportunities with its big target being hepatitis delta virus. Eiger's first therapy Zokinvy just got approved which nets the company an important Prior...
PALO ALTO, Calif., Nov. 25, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra...
Eiger (EIGR) gets FDA approval for Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.
The FDA approved Eiger Biopharmaceuticals Inc (NASDAQ: EIGR)'s lonfarnib Friday for the treatment of Hutchinson-Gilford Progeria Syndrome, commonly referred to as progeria, as well as processi...
PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of first-in-class therapies for serious rare an...
PALO ALTO, Calif., Nov. 2, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted, first-in-class therapies for serious...
Eiger (EIGR) gains on positive results from the ILIAD study on peginterferon lambda-1a (lambda) in outpatients with mild-to-moderate COVID-19.
Eiger BioPharmaceuticals: Peginterferon Lambda COVID-19 Data Very Positive
Investors were excited about the company's positive results from a COVID-19 clinical study
Eiger (EIGR) declines on disappointing study results on candidate, peginterferon lambda-1a (lambda), in outpatients with mild and uncomplicated COVID-19.
The company reported disappointing news from a clinical study targeting COVID-19 outpatients.
Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR) has announced disappointing results from an investigator-sponsored study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplic...
Short-term catalyst is the near-certain approval of lonafarnib in HGPS.
Investors need to pay close attention to Eiger BioPharmaceuticals (EIGR) stock based on the movements in the options market lately.
PALO ALTO, Calif., Aug. 31, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals (EIGR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Coronavirus Pandemic: Regeneron And Eiger BioPharmaceuticals Positioned To Benefit From Opportunity In Treating Early Stage And At-Risk Patients
A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.
Eiger BioPharma (EIGR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
PALO ALTO, Calif., May 29, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced today that, due to public health and safety concerns related to the COVID-19 global pand...
PALO ALTO, Calif., May 26, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-...
PALO ALTO, Calif., May 19, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-...
Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Eiger BioPharmaceuticals: Promising COVID-19 Effort With Peginterferon Lambda Just Entering Clinical Trials
As of late, it has definitely been a great time to be an investor Eiger BioPharmaceuticals
Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in c...
Eiger BioPharma (EIGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
EIGR has an NDA upcoming for an ultrarare disease, but another phase 3 trial ongoing for the first antiviral against the hepatitis D virus.
Tuesday was a breakout day for a few biotech companies, and that was the case even before news broke that the U.S. and China would be meeting at the G20 meeting in Japan.
About EIGR
Eiger BioPharmaceuticals, a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria ... [Read more...]
| Industry Biotechnology | |
| CEO David Cory | Employees 29 |
| Stock Exchange NASDAQ | Ticker Symbol EIGR |
Analyst Forecasts
According to 6 analysts, the average rating for EIGR stock is "Strong Buy." The 12-month stock price forecast is 31.67, which is an increase of 204.81% from the latest price.